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Summary
Background Most data on mortality and prognostic factors in patients with heart failure come from North America 
and Europe, with little information from other regions. Here, in the International Congestive Heart Failure (INTER-
CHF) study, we aimed to measure mortality at 1 year in patients with heart failure in Africa, China, India, the Middle 
East, southeast Asia and South America; we also explored demographic, clinical, and socioeconomic variables 
associated with mortality. 
Methods We enrolled consecutive patients with heart failure (3695 [66%] clinic outpatients, 2105 [34%] hospital in 
patients) from 108 centres in six geographical regions. We recorded baseline demographic and clinical characteristics 
and followed up patients at 6 months and 1 year from enrolment to record symptoms, medications, and outcomes. 
Time to death was studied with Cox proportional hazards models adjusted for demographic and clinical variables, 
medications, socioeconomic variables, and region. We used the explained risk statistic to calculate the relative 
contribution of each level of adjustment to the risk of death.
Findings We enrolled 5823 patients within 1 year (with 98% follow-up). Overall mortality was 16·5%: highest in Africa 
(34%) and India (23%), intermediate in southeast Asia (15%), and lowest in China (7%), South America (9%), and the 
Middle East (9%). Regional differences persisted after multivariable adjustment. Independent predictors of mortality 
included cardiac variables (New York Heart Association Functional Class III or IV, previous admission for heart 
failure, and valve disease) and non-cardiac variables (body-mass index, chronic kidney disease, and chronic obstructive 
pulmonary disease). 46% of mortality risk was explained by multivariable modelling with these variables; however, 
the remainder was unexplained.  
Interpretation Marked regional differences in mortality in patients with heart failure persisted after multivariable 
adjustment for cardiac and non-cardiac factors. Therefore, variations in mortality between regions could be the result 
of health-care infrastructure, quality and access, or environmental and genetic factors. Further studies in large, global 
cohorts are needed.
Funding The study was supported by Novartis.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Heart failure is an important global health problem, 
affecting about 26 million people worldwide;1 it is 
associated with high mortality and is estimated to have 
cost about US$100 billion in 2012.2 Most data on 
outcomes in patients with heart failure come from North 
America and Europe, with much less information from 
Africa, Asia, the Middle East, and South America.3–5 The 
few data from low-income and middle-income countries 
(LMIC) suggest that mortality in patients with heart 
failure in these countries is greater than that in high-
income countries.6–8 However, reasons for variation in 
out comes between regions remain unclear. Therefore, 
we designed a prospective registry of patients with heart 
failure in 16  countries in Africa, Asia, the Middle East, 
and South America to document 1-year mortality in 
patients from these regions, and to explore variables 
associated with mortality. 
Methods 
Study design and participants 
The International Congestive Heart Failure Study 
(INTER-CHF) is a prospective cohort study, conducted in 
108 centres in 16 countries with follow-up at 12 months. 
The rationale and design for this study have been 
published elsewhere,9 but are briefly described here. 
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We enrolled patients with a clinical diagnosis of heart 
failure in Africa (Mozambique, Nigeria, South Africa, 
Sudan, and Uganda), China, India, the Middle East 
(Egypt, Qatar, and Saudi Arabia), southeast Asia 
(Malaysia, and the Philippines), and South America 
(Argentina, Chile, Colombia, and Ecuador; appendix). 
We included consecutive heart failure patients from 
outpatient clinics and inpatient hospital wards at 
participating centres. We aimed to recruit two-thirds of 
the study population from out patient clinics since most 
previous data on heart failure have come from hospital 
inpatients.4–7,10 Patients were aged 18 years or older and 
enrolled from academic health-care centres, community 
health centres, and specialist and primary care clinics. 
Where feasible, at least one centre in each country was in 
a rural area. We excluded patients with severe non-
cardiac diseases that could affect survival within 1 year, 
and patients who were difficult to follow-up (for example, 
because of their migratory status). 
The study was approved by institutional review boards 
or independent ethics committees at participating sites 
and the international coordinating centre (McMaster 
University, Hamilton, ON, Canada). Participants or their 
substitute decision maker provided written informed 
consent.
Procedures 
At enrolment, we recorded information on demographics, 
clinical factors, medications, and socioeconomic factors. 
Echocardiograms, if done for clinical care, were used for 
information about left ventricular systolic function and 
valve disease. Left ventricular ejection fraction (LVEF) 
was defined as reduced when  less than 40%.11 Valvular 
heart disease was defined as the presence of at least 
moderate stenosis or regurgitation in at least one cardiac 
valve. 
A local physician determined the cause of heart failure 
using all available clinical data. Although we did not 
specify that patients had to meet specific criteria to be 
included, we prospectively collected information to assess 
the proportion of participants who met the Boston criteria 
for heart failure.12,13 Patients had follow-up visits at 
6  months and 12 months, at which symptoms, medi-
cations and outcomes were recorded. 
Outcomes 
Primary outcome was time to all-cause mortality 
within  1  year. Cause of death was also recorded, and 
categorised by local investigators as cardiac, non-cardiac, 
or unknown. 
Statistical analysis 
We used univariable and multivariable Cox proportional 
hazards models for time-to-event analysis of mortality. 
We verified the proportionality assumptions with 
standard log[-log(survival)] plots. In model 1, we included 
17 variables from the Meta-Analysis Global Group in 
Chronic Heart Failure (MAGGIC) criteria,14 plus socio-
economic variables and region, in a multivariable model. 
These variables (see appendix) were divided into 
demographic variables, clinical variables, medications, 
socio economic variables, and region to determine the 
effect of each level of adjustment on the conditional 
instan taneous risk (hazard) of death within 1 year. To 
calculate regional hazard of death, we used South 
America as the reference region because it had a low 
death rate. 
In model 2, we performed a second analysis using the 
same variables as in model 1, but excluded data derived 
from echocardiograms (LVEF, valve disease).
We conducted a sensitivity analysis including patients 
who had clinical variables that fulfilled the Boston heart 
Research in Context
Evidence before this study
We searched MEDLINE on Feb 10, 2017, for English-language 
cohort studies published since 1990 of patients with heart 
failure recruited from outpatient clinics or hospital settings. 
Studies had to include data on mortality. We used the search 
terms “heart failure”, “global”, “international”, “worldwide”, 
“outcomes”, and “mortality”. There were no cohort studies 
identified that included patients with heart failure from 
different world regions that compared outcomes.  
Added value of this study
The current study adds to the findings of previously published 
local registries and randomised controlled trials by directly 
demonstrating that mortality in patients with heart failure 
was highest in Africa and India, intermediate in southeast 
Asia, and lowest in China, South America, and the Middle East. 
These differences persisted after adjustment for clinical 
variables, medication use, and socioeconomic variables, 
suggesting that a large part of the variations in mortality 
could be the result of unrecorded or unknown factors.
Implications of all of the available evidence
The evidence suggests that there are important differences 
between regions in death rates for patients with heart failure. 
In general, patients with heart failure from richer regions have 
lower mortality than do patients from poorer regions. These 
regional differences persist after adjustment for risk factors 
and treatments, which only explained about half of the risk of 
death. Therefore, the data suggest that regional variations in 
heart failure outcomes might be due to factors that are not 
well described or measured in the current literature. These 
include health-care quality, access, and infrastructure as well 
as environmental factors and genetics. Further research into 
these factors is, therefore, warranted.
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failure criteria.11 We did further analyses by admission 
status at enrolment (ie, hospital inpatients or clinic 
outpatients). In Cox proportional hazards models, we 
calculated the explained risk statistic to measure the 
Overall 
(N=5823)
Africa 
(N=1294)
India 
(N=858)
SoutheastAsia 
(N=811)
Middle East 
(N=1000)
China 
(N=991)
South America 
(N=869)
Demographic variables
Age (years) 59 (15) 53 (14) 56 (15) 57 (14) 56 (16) 66 (16) 67 (15)
Male sex 3495 (61%) 662 (52%) 531 (62%) 474 (59%) 721 (72%) 570 (57%) 537 (61%)
Clinical variables
Body-mass index (kg/m2) 26 (6·1) 26 (6·1) 23 (6·2) 26 (6) 30 (6) 24 (6.3) 29 (6.2)
Systolic blood pressure (mm Hg) 125 (23) 124 (21) 125 (21) 128 (23) 126 (22) 126 (22) 123 (24)
Diastolic blood pressure (mm Hg) 76 (13) 79 (16) 77 (12) 76 (12) 72 (13) 77 (12) 75 (13)
History of diabetes mellitus 1728 (29%) 201 (17%) 217 (26%) 328 (41%) 541 (57%) 216 (19%) 225 (21%)
History of chronic kidney disease 487 (8%) 45 (4%) 30 (3%) 107 (13%) 121 (12%) 67 (6%) 117 (11%)
Current tobacco use 554 (6%) 78 (4%) 102 (7%) 81 (6%) 132 (7%) 106 (8%) 55 (4%)
History of chronic obstructive pulmonary 
disease
450 (6%) 26 (2%) 139 (16%) 35 (4%) 41 (4%) 99 (8%) 110 (10%)
Reduced left ventricular ejection fraction 
(<40%)*
2486 (50%) 526 (54%) 392 (53%) 247 (39%) 743 (73%) 212 (27%) 366 (53%)
Valve disease*† 2286 (46%) 582 (57%) 309 (42%) 265 (40%) 479 (50%) 306 (41%) 345 (48%)
NYHA functional class III or IV 2470 (40%) 702 (56%) 415 (50%) 127 (16%) 360 (37%) 574 (56%) 292 (32%)
Admission for heart failure in previous year 1567 (27%) 420 (36%) 122 (14%) 285 (35%) 219 (22%) 308 (34%) 213 (28%)
Recruited as hospital inpatient 2105 (34%) 616 (48%) 389 (45%) 187 (23%) 310 (31%) 367 (35%) 236 (26%)
Main cause of heart failure
Ischaemic heart disease 2433 (39%) 242 (20%) 399 (46%) 449 (56%) 521 (50%) 519 (45%) 303 (25%)
Hypertensive heart disease 1096 (17%) 392 (35%) 116 (14%) 115 (15%) 93 (10%) 165 (14%) 215 (21%)
Idiopathic dilated cardiomyopathy 838 (12%) 212 (14%) 118 (11%) 31 (3%) 220 (18%) 141 (15%) 116 (15%)
Valvular heart disease 739 (11%) 185 (11%) 135 (12%) 122 (12%) 93 (8%) 97 (11%) 107 (13%)
Endocrine or metabolic disease 224 (4%) 67 (5%) 36 (4%) 46 (6%) 14 (1%) 31 (3%) 30 (4%)
Hypertrophic cardiomyopathy 71 (1%) 3 (0·2%) 15 (1·7%) 7 (0·8%) 6 (0·6%) 14 (1·6%) 26 (3·4%)
Congenital heart disease 57 (0·5%) 4 (0·1%) 10 (0·5%) 11 (1%) 7 (0·3%) 13 (1·2%) 12 (1·5%)
Alcohol or drugs 68 (0·4%) 22 (0·7%) 6 (0·2%) 6 (0·3%) 19 (0·6%) 7 (0·4%) 8 (0·5%)
Cardiac medications
Beta blocker 3768 (67%) 634 (48%) 495 (57%) 543 (66%) 866 (85%) 594 (60%) 636 (73%)
ACE inhibitor 2924 (49%) 774 (59%) 449 (51%) 383 (46%) 641 (62%) 336 (34%) 341 (40%)
Angiotensin receptor blocker 1443 (24%) 226 (19%) 143 (17%) 215 (27%) 191 (20%) 323 (29%) 345 (36%)
ACE inhibitor/angiotensin receptor blocker 4322 (74%) 990 (78%) 586 (68%) 593 (73%) 828 (82%) 654 (64%) 671 (76%)
Aldosterone inhibitor 2913 (48%) 787 (59%) 421 (47%) 229 (27%) 480 (46%) 533 (56%) 463 (55%)
Loop diuretic 4414 (78%) 1214 (94%) 691 (81%) 361 (45%) 878 (88%) 598 (61%) 672 (78%)
Digoxin 1550 (26%) 443 (32%) 224 (25%) 241 (29%) 186 (18%) 262 (29%) 194 (25%)
Long-acting nitrate 1075 (15%) 58 (5%) 114 (13%) 188 (23%) 256 (25%) 360 (31%) 99 (8%)
Aspirin 3293 (56%) 558 (46%) 440 (52%) 469 (58%) 753 (75%) 620 (58%) 453 (46%)
Warfarin 858 (14%) 222 (17%) 84 (10%) 81 (10%) 194 (20%) 97 (10%) 180 (22%)
Socioeconomic factors
Illiterate 1319 (15%) 495 (43%) 229 (29%) 20 (2%) 303 (36%) 210 (15%) 62 (4%)
Education ≥ grade 5 level 2496 (42%) 714 (61%) 428 (56%) 161 (20%) 464 (54%) 423 (37%) 306 (29%)
Education grade 6 –10 level 1382 (23%) 178 (13%) 135 (15%) 312 (37%) 207 (19%) 285 (30%) 265 (32%)
Education grade 11–12 level 1047 (17%) 208 (13%) 183 (18%) 175 (19%) 161 (13%) 170 (18%) 150 (19%)
Education post secondary 896 (13%) 193 (13%) 112 (11%) 163 (18%) 168 (13%) 113 (11%) 147 (17%)
Dwelling in rural area 2080 (36%) 414 (42%) 492 (48%) 298 (37%) 261 (26%) 434 (44%) 181 (21%)
Health insurance 3345 (61%) 416 (33%) 166 (19%) 357 (44%) 743 (74%) 906 (91%) 757 (76%)
Data adjusted for age and sex. Data are mean (SD) or n (%). NYHA=New York Heart Association. ACE=angiotensin converting enzyme. *Data available for 4716 patients 
(81%) who had echocardiograms. †Valve disease defined as moderate or greater stenosis or regurgitation in a cardiac valve on echocardiogram; may co-exist with any of the 
main causes of heart failure.
Table 1: Baseline demographic and clinical characteristics
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change in randomness (entropy) due to the introduction 
or removal of a covariate.15 The explained risk statistics 
were calculated using R software version 3.2.5, 
(R  Foundation for Statistical Computing, Vienna, 
Austria). All other analyses were performed using SAS 
version 9.4 for UNIX (SAS Institute Inc, Cary, NC, USA). 
Given the observational nature of this study, reported 
p values are considered as informative statistics. We set 
the threshold of p<0·001 for a finding to be considered as 
persuasive  evidence of a meaningful finding, because 
of the number of research questions addressed in 
analysis 
Results
Between September 10, 2012, and February 21, 2014, we 
screened 7176 consecutive patients for eligibility and 
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Figure 1: Unadjusted mortality at 1 year, by region and cause
Univariable analysis Multivariable analysis
Hazard ratio  
(95% CI)
p χ²* Hazard ratio 
(95% CI)
p χ²
Demographic variables
Age (per 10 year increase) 1 (1·0–1·1) 0·28 1·2 1·1 (1·05–1·17) 0·005 7·7
Male sex 1 (0·9–1·2) 0·84 0 1·0 (0·9–1·3) 0·7 0·1
Clinical variables
Enrolled as hospital inpatient 2·9 (2·5–3·6) <0·0001 158 1·9 (1·6–2·2) <0·0001 44
Valve disease on echocardiogram† 2·0 (1·7–2·4) <0·0001 64 1·6 (1.3 – 1.9) <0·0001 25
Admission for hearth failure in previous year 1·9 (1·6–2·2) <0·0001 60 1·6 (1·3–1·9) <0·0001 25
History of chronic kidney disease 1·7 (1·3–2·2) <0·0001 19 1·9 (1·5–2·5) <0·0001 24
Systolic blood pressure (per 10 mmHg increase) 0·9 (0·8–0·9) <0·0001 30 0.92 (0.88 – 0.96) <0·0001 17
NYHA functional class III or IV (vs class I and II) 2·2 (1·8–2·6) <0·0001 83 1·4 (1·2–1·7) 0·0003 13
Body mass index (per 1 kg/m2 increase) 0·94 (0·93–0·96) <0·0001 52 0·97 (0·96–0·99) 0·001 11
History of chronic obstructive pulmonary disease 1·6 (1·3–2·1) 0·0002 14 1·6 (1·2–2·1) 0·001 11
History of diabetes mellitus 1·1 (0·9–1·3) 0·26 1·3 1·2 (1·0–1·5) 0·06 3·5
Reduced left ventricular function (EF <40%) 1·3 (1·1–1·5) 0·003 8·7 1·1 (0·9–1·4) 0·2 1·6
Current tobacco use 0·8 (0·6–1·1)  0·22 1·5 0·9 (0·7–1·3) 0·69 0·1
Ischaemic cause of heart failure 1·0 (0·8–1·1) 0·66 0·2 1·0 (0·8–1·3) 0·72 0·1
Medications
ACE inhibitor or ARB use 0·7(0·6–0·8) <0·0001 21 0·8 (0·7–0·9) 0·01 5·8
Digoxin use 1·0 (0·8–1·2) 0·83 0 0·80 (0·7–0·9) 0·03 4·7
Beta blocker use 0·6 (0·5–0·7) <0·0001 33 0·9 (0·7–1·1) 0·17 1·9
Aldosterone inhibitor use 1·0 (0·9–1·2) 0·60 0·3 1·0 (0·8–1·2) 0·95 0
Socioeconomic factors
Illiterate 1·8 (1·5–2·1) <0·0001 40 1·2 (0·9–1·5) 0·13 2·2
Dwelling in rural area 1·4 (1·2–1·7) <0·0001 17 1·2 (1·0–1·4) 0·12 2·4
No health insurance 1·6 (1·3–1·9) <0·0001 29 0·9 (0·7–1·0) 0·12 2·4
Region (vs South America)
Africa 3·7 (2·7–5·1) <0·0001 60 3·8 (2·6–5·5) <0·0001 48
India 2·9 (2·1–4·1) <0·0001 37 2·9 (1·9–4·3) <0·0001 28
Southeast Asia 1·9 (1·3–2·8) 0·0004 12 2·6 (1·7–3·9) <0·0001 21
Middle East 1·2 (0·8–1·7) 0·43 0·6 1·3 (0·9–1·9) 0·23 1·4
China 0·8 (0·6–1·3) 0·86 0·4 0·7 (0·4–1·1) 0·14 2·1
ARB=angiotensin receptor blocker; EF=ejection fraction; NYHA=New York Heart Association.*Degrees of freedom=1 for all tests. †Defined as moderate or greater stenosis or 
regurgitation in a cardiac valve on echocardiography. N=4347; 565 deaths; global χ2=519; p <0·0001
Table 2: Variables associated with all-cause mortality at 1 year
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enrolled 5823 participants (81%). Table 1 shows baseline 
characteristics, adjusted for age and sex, by region; 
further cohort data have been reported previously.16 Mean 
age of the cohort was 59 years (SD 15); 2328 (39%) were 
female, 3549 (64%) had a history of hypertension, 
1728  (29%) had a history of diabetes mellitus, 487 (8%) 
had a history of chronic kidney disease, and 2486 (50%) 
had a LVEF  less than 40%. The cause of heart failure was 
ischaemia in 2433 (39%), hypertension in 1096 (17%), 
idiopathic dilated cardiomyopathy in 838 (12%), and 
primary valve disease in 739 (11%). 1319 (15%) of 
participants were illiterate and 2477 (39%) had no health 
insurance. As per our study design, 3695 participants 
(66%) were recruited from outpatient clinics and 
2105  (34%) from inpatient hospital wards; 2080 (36%) 
were recruited in rural settings. 
Follow-up data at 12 months were available in 
5689/5823  (98%) of patients: 811/811 (100%) in southeast 
Asia, 989/991 (100%) in China, 856/858 (100%) in India, 
995/1000 (99%) in the Middle East, 830/869 (95%) in 
South America, and 1208/1294 (93%) in Africa. 
Data from echocardiograms were available for 
4716 patients (81%). In model 2, with data derived from 
echo cardiograms excluded, the number of patients for 
which all data were available increased from 4347 patients 
with 565 deaths (in model 1) to 5341 patients with 
766 deaths. The events per variable (EPV) of 565 deaths/ 
21 variables=27 (model 1), and 766 deaths/19 variables=40 
(model 2), are well above the recommended threshold of 
10 EPV, therefore minimising bias in parameter esti-
mates of our Cox proportional hazards model.17,18 
Findings from model 1 are reported here, and results 
from model 2 are shown in the appendix. 
Unadjusted all-cause mortality within 1 year was 
16·5% (95% CI 15·4–17·6), and varied substantially 
between regions. Mean age at time of death was 56 years 
(SD 16) in Africa, 59 years (15) in India, 57 years (15) in 
southeast Asia, 60 years (14) in the Middle East, 
69  years  (13) in China, and 72 years (14) in South 
America. Despite being in the youngest cohorts at 
baseline, patients in Africa and India had the highest 
mortality (33·6% [95% CI 30·2–37·4]), 23·3% 
[19·9–27·0]), respectively), and participants from south-
east Asian had an intermediate rate (15·0% [12·4–18·0]), 
compared with patients in China, South America and 
the Middle East patients who had the lowest rates of 
death (7 ·3% [5·7–9·3], 9·1% [7·1–11·4] and 9·4% 
[7·5–11·5], respectively). 
Of the 858 deaths within 1 year, cardiac deaths were 
more common than non-cardiac deaths (398 [46%] and 
136 [16%], respectively), and deaths from an unknown 
cause (324 [38%]). The proportion of deaths from an 
unknown cause was much higher in Africa (189 deaths, 
55%) than in other regions (figure 1). When we excluded 
Africa from analysis, 282 (55%) deaths were from cardiac 
causes, 99 (19%) from non-cardiac causes, and 135 (26%) 
from unknown cause. 
In unadjusted analyses, variables associated with death 
within 1 year included clinical variables, medi cations, 
socioeconomic variables and region (table 2). After 
multivariable adjustment, clinical and demographic 
variables independently associated with death within 
1  year included: age  (hazard ratio [HR] 1·1; 95% CI 
1·05–1·17), systolic blood pressure (0·92 per 10 mm Hg 
increase; 0·88–0·96), body mass index (0·97 per 1 kg/m2 
increase; 0·96–0·99), history of chronic kidney disease 
(1·9; 1·5–2·5), New York Heart Association (NYHA) 
functional class III or IV heart failure (1·4; 1·2–1·7), 
enrolment as a hospital inpatient (1·9; 1·6–2·2), 
admission for heart failure in the previous year (1·6; 
1·3–1·9), history of chronic obstructive pulmonary 
disease (1·6; 1·2–2·1), and valve disease shown on echo-
cardiograms (1·6; 1·3–1·9). Medications associated with 
death rates at 1 year were ACE inhibitors or angiotensin 
receptor blockers (0·8;  0·7–0·9), and di goxin use at 
enrolment (0·8; 0·7–0·9).  With South America as the 
reference, the variable of region was associated with 
1-year mortality in Africa (3·8; 2·6–5·5), India (2·9; 
1·9–4·3), and southeast Asia (2·6; 1·7–3·9). Figure 2 
shows unadjusted and adjusted survival curves.  
Figure 2: Unadjusted and adjusted survival curves by region
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In our analyses of cause-specific mortality, we noted 
that for cardiac death alone, results were similar to those 
for all-cause deaths: patients in Africa (HR 2·3; 95% CI 
1·4–3·8) and India (2·5; 1·5–4·2) were at highest hazard 
of cardiac death, followed by those in southeast Asian 
(2·0; 1·2–3·4), with no increased hazard in patients in 
the Middle East (1·0; 0·6–7·7) or China (0·7, 0·4–1·2), 
compared with the South American cohort. Likewise, for 
non-cardiac deaths, participants in Africa (2·7; 1·2–6·2) 
and India (2·4; 1·0–5·9) were at highest hazard, followed 
by participants in southeast Asia (2·0; 0·8–4·9), the 
Middle East (1·4, 0·6–3.4) and China (0·5; 0·2–1·3), 
compared with South American patients.
When data were stratified by patients’ admission status, 
we noted that of the 2105 patients recruited as hospital 
inpatients, unadjusted mortality within 1 year was 
markedly higher (30·6%, 95% CI 28·0–33·3), than in the 
3695 patients recruited from outpatient clinics (9·6%, 
8·6–10·6) (figure 3). As in the overall cohort, patients 
recruited as hospital inpatients in Africa had the highest 
adjusted hazard of death within 1 year (HR 3·7; 95% CI 
2·2–6·2), followed by inpatients in India (2·4; 1·4–4·0) 
and southeast Asia (2·4; 1·3–4·4), with no increased 
hazard of death in the Middle East (1·1; 0·6–1·9), or 
China (0·4; 0·2–0·8), compared with the South American 
cohort. For patients recruited as outpatients, findings 
were similar, with highest hazard of death in Africa (4·2; 
2·3–7·5) and India (4·1; 2·2–7·6), followed by southeast 
Asia (3·3; 1·9–5·9), the Middle East (1·7; 1·0–3·0), and 
China (1·2; 0·8–2·2).
Of the 5823 participants in INTER-CHF, 3189 (55%) 
had all required variables measured for the Boston 
Criteria for heart failure. Of these 3189 participants, 
2597 (81%) had either definite or probable heart failure. In 
this stratum patients with either definite of probable heart 
failure, regional patterns in hazard ratios noted for the 
overall cohort remained: participants in Africa (HR 2·8; 
95% CI 1·7–4·3) and India (2·7; 1·6–4·3) had the highest 
hazard of death, followed by those in southeast Asia 
(2·2; 1·3–3·9), the Middle East (0·9; 0·6–1·5), and China 
(0·6; 0·3–1·1), compared with South American patients. 
We used the explained-risk statistic15 to determine the 
relative contributions of each of demographic and clinical 
variable, medications, socioeconomic variable and region 
to the risk of death within 1 year in the overall cohort. 
These variables, together, explained 46% of the risk of 
death. Of the explained risk, clinical variables alone 
accounted for 53%, and region for 35%, with lesser 
contributions from demographic variables, medications 
,and socioeconomic variables (2% for each; table 3). 
Discussion
We have observed substantial variations in mortality 
between regions in patients with heart failure—rates 
were higher in poorer regions and lower in richer regions, 
and differences persisted after multivariable modelling. 
Although data from international studies in clinic 
outpatients (that is, patients with chronic heart failure) 
are few, they do also suggest regional differences in heart 
failure outcomes. In an analysis of regional differences 
observed in the PARADIGM-HF study19 (a randomised 
trial of sacubitril/valsartan versus enalapril, in which 
10 521 patients from 1043 centres in 47 countries entered 
the run-in period), Kristensen and colleagues analysed 
data from 8399 patients with chronic heart failure with 
reduced LVEF in six geographical regions. They showed 
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Figure 3: Unadjusted mortality at 1 year, by admission status at recruitment and region
Value (%) Standard 
error (%)
Demographic variables 0·2 0·4
Demographic + clinical variables 35 2·7
Only demographic variables 0·1 0·1
Only clinical variables 35 2·7
Demographic + clinical variables + 
medications
36 2·7
Only demographic variables 0 0·1
Only clinical variables 33 2·8
Only medications 2·1 1
Demographic + clinical + medications + 
socioeconomic variables
39 2·6
Only demographic variables 0·2 0·3
Only clinical variables 29 2·8
Only medications 1·7 0·9
Only socioeconomic variables 3·4 1·2
Demographic + clinical + medications + 
socioeconomic variables + region
46 2·4
Only demographic variables 0·7 0·6
Only clinical variables 25 2·6
Only medications 1·1 0·6
Only socioeconomic variables 0·7 0·5
Only region 12 3·0
Demographic, clinical, medication, socioeconomic variables and region account 
for 46% of explained relative risk of death in the overall cohort. The remainder of 
risk is unexplained. N=4347; 565 events.
Table 3: Explained risk analysis for independent variables included in 
Cox proportional hazards (model 1) of all-cause mortality in the overall 
cohort at 1 year
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that the adjusted risk of cardiovascular death was greater 
in Latin America and Asia-Pacific than in North America 
and Europe; patients from the Asia-Pacific region were 
also significantly younger than patients from western 
countries. A pooled analysis of 53  local and regional 
studies also reported that the mean age of patients with 
heart failure in LMIC was a decade younger than in high-
income countries.8 In INTER-CHF, patients in Africa, 
India, and southeast Asia were approximately 10 years 
younger than patients in South America and China, but 
had much higher mortality. This finding may be related 
to patients with heart failure presenting later for medical 
care (that is, when they are sicker) in low-income com-
pared with high-income regions, and late presen tation 
being associated with a worse prognosis.20 This finding 
may also be related to the overall lower life expectancies 
in LMIC compared with high-income countries.21
Study participants with acute heart failure enrolled as 
inpatients in clinical trials have shown that patients from 
North America and Europe had lower mortality rates 
than did patients from South America and Asia, with few 
data from the Middle East, Africa, South Asia or 
China.10,22,23 In a retrospective analysis of the ASCEND-HF 
trial24 (a randomised trial of nesiritide versus placebo in 
7141  hospitalised patients with acute heart failure from 
398 sites in 30 countries), patients from Latin America 
had the highest adjusted 180-day mortality (17·3%), 
followed by western Europe, North America, Asia-Pacific, 
with Central Europe (9·3%) having the lowest mortality. 
Local registries have also reported data on mortality in 
inpatients with heart failure. A study of 1009 patients 
with heart failure admitted to hospitals in sub-Saharan 
Africa reported an unadjusted 6-month mortality of 
17·8%, which is probably an underestimate because of 
the substantial losses to follow-up.25 In a registry of 
1205 patients hospitalised with heart failure in India, the 
90-day mortality rate was 24·3%.26 In a hospital registry 
of 5005 patients with heart failure from Gulf states, 
mortality at 1 year was 20%.27 Therefore, data from other 
studies accord with our findings of variations in 
outcomes between regions and also high mortality by 
region. Our study also provides new data on outcomes in 
outpatients with chronic heart failure, and in several 
countries and regions not previously studied. 
In INTER-CHF, both cardiac and non-cardiac factors 
were associated with all-cause mortality, consistent with 
data from western populations.28 However, in our study, 
multivariable adjustment including these factors only 
explained about half the mortality risk, the remainder 
being unexplained. Importantly, when compared with 
other regions in this study, patients in Africa were much 
younger, more symptomatic, more often treated with 
digoxin, had little education, low rates of health-
insurance, and were more often from a rural area. Similar 
patterns were observed in India. These were the countries 
with highest mortality. Therefore, country-level, environ-
mental, wealth, and healthcare infrastructure, quality and 
access factors would need to be addressed if these 
differences in outcomes were to be further explained. 
Indeed, in a systematic review by Callender and 
colleagues8 of earlier regional heart failure studies, 
higher mortality in lower-income regions was thought to 
be partly the result of differing health systems, quality of 
care, and variations in health-care access. In addition, 
genetic and genomic factors may also influence regional 
variations in heart failure outcomes, but were not 
recorded in INTER-CHF. Therefore, measuring and 
understanding health systems, environmental and 
societal issues, and genetic and genomic markers in 
future international heart failure studies could help in 
understanding the causes of the regional variations in 
outcomes. Information on health systems could assist in 
developing strategies to further reduce mortality in 
patients with heart failure.
The 5823 patients with heart failure enrolled in this 
study from 108 centres in 16 countries constitute a large 
study of heart failure in Africa, Asia, the Middle East and 
South America. However, some randomised trials in 
patients with heart failure that included different regions 
were larger.19,24 By using a standardised protocol and 
approach, comparisons of patient characteristics and 
outcomes between regions are possible. Furthermore, 
the high follow-up rate of 98% gives confidence in our 
findings. As with most registries, we were unable to 
randomly sample clinical sites or populations, for 
practical reasons. However, data from INTER-CHF are 
similar to data collected elsewhere in other studies.8,19 
Although representativeness and potential ascertainment 
bias are inherent challenges in data collection for 
registries, the consistent data from other studies from 
specific regions validate our findings. Furthermore, 
variability in decisions about the causes of heart failure 
and death are possible, but are a reality of clinical 
practice, not only in LMIC but also in western countries. 
Unpublished data from the PURE study, which is 
community based, also show that mortality after a 
diagnosis of heart failure was lowest in high-income 
countries, intermediate in middle-income countries and 
highest in low-income countries. 
In this heart failure cohort study in 16 countries, 
mortality was highest in Africa and India, intermediate 
in southeast Asia, and lowest in China, South America, 
and the Middle East. These regional differences persisted 
after multivariable adjustment including both cardiac 
and non-cardiac factors. Therefore, the large regional 
differences in death in patients with heart failure could 
be influenced by unmeasured variables, requiring 
further study in large, global cohorts of patients with 
heart failure.
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